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With better matching due to genomic tissue typing and improved
immunosuppression, hematopoietic stem cell transplant (HSCT)
usingHLA-matched unrelated donors (URD) have similar outcome
as using HLA-identical sibling donors (sib). Do some leukemia pa-
tients benefit from an URD transplant, because of a stronger graft-
versus-leukemia (GVL) effect? We analyzed the outcome in 941
URD (8/8 HLA-allele matched) transplants, compared to 3158
sib HSCT for acute leukemia (AML and ALL) and chronic myeloid
leukemia (CML) receiving myeloablative conditioning between
1995–2004 and reported to the CIBMTR. Transplant-related mor-
tality (TRM), relapse, survival and leukemia-free-survival (LFS)
were compared for each disease. In a Cox proportional hazard re-
gression model including variables important for outcome, acute
and chronic GVHD were added as time-dependent variables.
Results:Using URD vs. sib HSCT, TRMwas increased in early
AML (40% vs. 24%, p5 0.001), and advanced ALL or AML (44%
vs. 31%, p 5 0.01). Among other risk factors, TRM was associated
with URD (p\0.001), advanced disease and increasing donor and
recipient age. Relapse was similar using URD or sib donors; AML
CR1 (5-year relapse 22% vs. 15%), intermediate disease (21% vs.
22%), advanced (43% vs. 46%), ALL early (15% vs. 23%), interme-
diate (36% vs. 32%) and advanced (48% vs. 52%), and for CML
early (5% vs. 6%), intermediate disease (16% vs. 22%) and blast cri-
sis (39% vs. 35%) (ns). In the Cox model, relapse was decreased in
patients with chronic GVHD for AML and ALL and in patients
with acute GVHD for CML. LFS was decreased in AML CR1
and advanced disease, and CML in blast crisis in URD vs. sib trans-
plants.To Conclude: Relapse was the same using URD compared
to sib HSCT, suggesting similar GVL effect. TRM was increased
and LFS was decreased using URD. Therefore, a sib donor should
be the first choice.
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Patients with chronic graft versus host disease (cGVHD) develop
antibody responses against a variety of target antigens 4–8 months
after hematopoietic stem cell transplantation (HSCT). These anti-
bodies can be specifically directed against amino acid polymor-
phisms that distinguish recipient from donor proteins (allo-
antibodies) or against normal or tumor-associated proteins that
are identical in the recipient and donor (auto-antibodies). We
used high-density protein microarrays (ProtoArray Protein Micro-
arrays V4, Invitrogen) to define the spectrum of antibody targets in
patients with cGVHD after HSCT. These protoarrays contain over
8,000 unique proteins individually spotted on nitrocellulose-coated
slides under native conditions. We used 1-year post-HSCT plasma
from 10 patients with cGVHD for antibody profiling. The reactiv-
ity of each patients cGVHD plasma was compared to a sample ob-
tained from the same patient prior to HSCT as well as to the
patients donor. All 30 arrays were from the same lot and were pro-
cessed by the same operator to enhance consistency. Plasma was
tested at a dilution of 1:500 and results were analyzed using Proto-
Array Prospector software (InVitrogen). Overall, 98 proteins were
targeted by cGVHDplasma and not by any of the pre-HSCTor do-
nor samples. Only 4 of the 98 proteins were targeted by 2 or more
cGVHD patients: protein kinase D3 (nu), ribonucleoprotein auto-
antigen (Ro/SSA), aldehyde dehydrogenase 7, and pyruvate dehy-
drogenase E1 component alpha subunit. Several proteins
identified by cGVHD antibodies were surface membrane or se-
creted proteins. These include PDGFR-alpha, PDGFR-beta,
FGFR-3, FGFR1 oncogene partner, adrenergic-beta receptor ki-
nase, poliovirus-receptor related-3, liprin beta-2, PMEPA1/
STAG1, neuropeptide-Y and serpin peptidase inhibitor. Antibodiesto these targets may have direct activating or inhibitory functional
effects or may initiate lysis of target cells through complement-me-
diated killing or antibody dependent cellular cytotoxicity. These ef-
fects can occur independently of effector T cell responses to these
proteins. These results demonstrate that patients with cGVHD de-
velop antibodies specific for a largely unique spectrum of target an-
tigens. These target antigens include surface membrane and
secreted proteins with potential functional capacities and this may
explain why B cell-directed therapy can improve some clinical man-
ifestations of cGVHD.
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We recently showed that high levels of B cell Activating Factor
(BAFF) after allogeneic hematopoietic stem cell transplantation
(HSCT) are associated with the development of chronic graft versus
host disease (cGVHD). Clinical responses observed after treatment
with rituximab (anti-CD20) also suggest a role for B cells in the im-
mune pathology of cGVHD, but the effect of rituximab on BAFF
levels and B cell repertoire in patients with cGVHD is unknown.
In patients with autoimmune disease treated with rituximab,
BAFF levels are elevated for 1–2months after B cell depletion. Since
high BAFF promotes survival and differentiation of human B cell
receptor (BCR)-activated (CD271) B cells into Ig-secreting cells
there is concern that high BAFF after rituximab may contribute
to clinical relapse. We studied 20 patients who received rituximab
(375 mg/m2/week  4 consecutive weeks for one or two cycles)
for steroid-refractory cGVHD. Patients were tested a median of
25 months after starting treatment. At the time of analysis, 9 had
progressive cGVHD, defined as worsening signs or symptoms in
any organ system or the requirement of additional systemic therapy
and 11 had stable or improved cGVHD, measured by reduction in
immune suppression and overall clinical assessment. While median
CD191 B cell number did not differ prior to rituximab treatment
(104.5  106/L versus 203.7  106/L, p 5 0.60, respectively),
CD191B cell number was significantly lower in the 9 patients
with worsening cGVHD at 25 months. Median BAFF levels were
also significantly higher in this group. To examine whether high
BAFF levels affected B cells in these patients, we examined BAFF-
R expression on CD191 B cells by flow cytometry. The median
fluorescence intensity (MFI) of BAFF-R expression was lower in
the progressive disease group compared to the stable/improved
group (0.62 versus 1.67 MFI, respectively). Finally, patients with
progressive cGVHD had increased proportions of CD271 B cells,
indicating that the pool of circulating B cells contains a higher frac-
tion of activated cells in these patients (Table 1). Despite persistent
B lymphopenia after rituximab, patients with progressive cGVHD
had significantly higher BAFF levels associated with a significant in-
crease in the proportion of CD271 BCR-activated circulating B
cells. These data provide a rationale for investigation of BAFF an-
tagonists in the treatment of cGVHD.BAFF levels & B cell phenotype 25 months after rituximab therapy for
cGVHD
Stable/Improved Progressed
(n 5 11) (n 5 9) p-valueTotal B Cell No.
(106)/L124.7 3.8 0.002BAFF (ng/ml) 2.58 7.72 0.01
% BAFF-R on B Cells 68.4 2.2 0.004
% CD27 on B Cells 9.0 70.9 0.04
